
Altimmune (ALT) Stock Forecast & Price Target
Altimmune (ALT) Analyst Ratings
Bulls say
Altimmune Inc. is positioned favorably in the biopharmaceutical sector due to its investigational product candidate, pemvidutide, which has demonstrated significant efficacy in clinical trials by achieving up to 76% liver fat reduction and notable improvements in ALT levels and cT1 biomarkers related to liver inflammation and fibrosis. The drug's favorable tolerability profile compared to existing therapies, combined with its unique dual mechanism of action targeting weight loss and liver function, enhances its potential marketability for both obesity and metabolic-associated liver diseases. Additionally, the FDA's openness to non-invasive endpoints for regulatory approval may expedite pemvidutide's pathway to market, thereby optimizing Altimmune's growth prospects and overall valuation.
Bears say
Altimmune Inc reported a net loss of $23.2 million in the fourth quarter of 2024, indicating significant financial strain as the company continues to develop its product candidate, pemvidutide. Despite pemvidutide's promising clinical results, including an average weight loss of 15.6% in a trial, the overall market adoption of similar therapies has been poor due to issues such as compliance challenges and limited clinical benefits. Furthermore, Altimmune faces multiple risks, including clinical development setbacks, intense competition, and potential challenges around commercialization and funding, all of which contribute to a negative outlook for the company’s stock.
This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.
Altimmune (ALT) Analyst Forecast & Price Prediction
Start investing in Altimmune (ALT)
Order type
Buy in
Order amount
Est. shares
0 shares